Stemline Therapeutics Prices $59.85 Million Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Stemline Therapeutics (STML) Prices 3.8M Common Offering at $15.75/Share
January 8, 2015 9:06 AM ESTStemline Therapeutics (Nasdaq: STML) announced the pricing of its previously announced underwritten public offering of 3,800,000 shares of its common stock at a public offering price of $15.75 per share. Stemline has also granted the underwriters a 30-day option to purchase up to an additional 570,000... More
